Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Berettyoujfalu – page 44

650 clinical trials in Berettyoujfalu, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Berettyoujfalu at a glance
650
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

650 trials in Berettyoujfalu

Open in trial search

Study on Bomedemstat for Patients with Essential Thrombocythemia Not Responding to or Intolerant of Hydroxyurea, Comparing with a Drug Combination

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Bomedemstat
  • Sponsor:Merck Sharp & Dohme LLC

Colitis ulcerative+1

Not recruiting

Study on the Long-term Safety of Vedolizumab for Children with Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Vedolizumab
  • Sponsor:Takeda Development Center Americas Inc.

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen - Cilag International

Study on Axatilimab for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Syndax Pharmaceuticals Inc.

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Polycythaemia vera

Not recruiting

Study on the Effects of Rusfertide (PTG-300) for Patients with Polycythemia Vera

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Rusfertide
  • Sponsor:Takeda Development Center Americas Inc.

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Incyte Corp.

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Partial seizures

Not recruiting

Study on the Safety and Effectiveness of Cenobamate for Children with Focal Seizures

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Cenobamate
  • Sponsor:Sk Life Science Inc.

Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Berettyoujfalu

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical trials focusing on primary prevention of atherosclerotic cardiovascular disease (ASCVD). The research examines advanced therapeutic approaches for reducing major adverse cardiovascular events in high-risk patients.

  • Cardiovascular Event Prevention
  • High-Risk Patient Management
  • Atherosclerosis Prevention

This groundbreaking research aims to evaluate new therapeutic strategies for improving cardiovascular outcomes in preventive cardiology, particularly focusing on patients who haven't yet experienced a cardiovascular event.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.